Zonisamide
Brand names: Zonegran
Zonisamide is a sulfonamide-derived antiepileptic drug used as adjunctive or monotherapy treatment for focal seizures, with or without secondary generalisation, in adults.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It blocks voltage-gated sodium and T-type calcium channels to stabilise neuronal membranes, and has weak carbonic anhydrase inhibitory activity.
Prescribing in practice
- It is a sulfonamide and can cause serious hypersensitivity reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis; stop immediately if a rash develops.
- It can reduce sweating and cause hyperthermia, particularly in children and in hot conditions, and may precipitate metabolic acidosis and renal stones.
- Antiepileptic treatment should not be stopped abruptly because of the risk of rebound seizures; withdraw gradually.
Monitoring
Monitor for signs of metabolic acidosis, hyperthermia, weight loss, and mood changes, and review renal function and bicarbonate as clinically indicated.
Counselling the patient
- Report any skin rash, fever, or mouth ulcers promptly as these may signal a serious reaction.
- Stay well hydrated and avoid overheating, especially in warm weather or during vigorous activity.
- Maintain good fluid intake to reduce the risk of kidney stones and report any new abdominal or flank pain.
Evidence & guidelines
Antiepileptic drugs carry an MHRA-recognised small increased risk of suicidal thoughts and behaviour, and patients should be monitored accordingly.
Reference: NICE NG217; EMA Zonegran SPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Multiple Organ Dysfunction Score (MODS) · Organ Failure Assessment
- International Staging System (ISS) for Multiple Myeloma · Multiple Myeloma
- Revised ISS (R-ISS) for Multiple Myeloma · Haematological Malignancy
- SLiM-CRAB Criteria for Multiple Myeloma · Myeloma
- Multiple Myeloma Response Criteria (IMWG 2016) · Myeloma
- IMPEDE-VTE Score for VTE Risk in Multiple Myeloma · Myeloma
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS